Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

PM Society Awards 2024 open for entries

Twist Health will be the headline sponsor of the awards for the second year running

- PMLiVE

Solving your biggest patient recruitment and retention challenges

Clinical trial patient recruitment and retention remains one of the key challenges to successfully bringing a new therapeutic to market. An estimated 85% of clinical trials face delays due to...

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

- PMLiVE

AstraZeneca’s Forxiga shows promise in paediatric type 2 diabetes trial

The prevalence of type 2 diabetes in children and adolescents is increasing globally

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

Over 82,000 people in the US will be be diagnosed with bladder cancer in 2023

Navigator – Revolutionize your patient recruitment and retention

Welcome to the new era in patient recruitment and retention

Innovative Trials

- PMLiVE

LifeArc to launch rare disease centres across the UK

One in 17 people will be affected by a rare disease at some point in their lives, amounting to around 3.5 million people in the UK

The Navigator – Revolutionize your patient recruitment and retention

Innovative Trials

- PMLiVE

Sharing Outcomes in MS at ECTRIMS 2023

During ECTRIMS 2023 congress, the Medscape Education Global team will be on site to present a poster of their educational outcomes.The poster, Virtual Patient Simulation Improves Neurologists’ Performance in Making...

Medscape Education

- PMLiVE

Shining a Light on Current Topics in Oncology

The Medscape Oncology team will be on the road again, this time in Madrid, Spain for ESMO 2023. This year, the team will be sharing education with a deep impact...

Medscape Education

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

Roche presents positive results for spinal muscular atrophy treatment Evrysdi in babies

The progressive neuromuscular disease affects approximately one in every 10,000 babies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links